Is Acticor Biotech SA halal to invest in?

According to Musaffa's Shariah screening methodology, Acticor Biotech SA (ALACT.PA) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Acticor Biotech SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Acticor Biotech SA using these criteria to determine its compliance status.

Can Muslims buy shares of Acticor Biotech SA?

Muslim investors may consider investing in Acticor Biotech SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Acticor Biotech SA classified as NOT HALAL?

Musaffa determines the Shariah status of Acticor Biotech SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Acticor Biotech SA updated?

The Shariah compliance status of Acticor Biotech SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Acticor Biotech SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Acticor Biotech SA?

You can check the latest Shariah compliance status of Acticor Biotech SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Acticor Biotech SA ALACT.PA

€0.25

Last Updated: Dec 09, 12:00 AM·XPAR

ALACT.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: September 12, 2024

Report Source: 2023 Annual Report

Analyst's Ratings for Acticor Biotech SA (ALACT.PA)

Based on 9 analysts giving stock ratings to Acticor Biotech SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Acticor Biotech SA. Stock Analysis ALACT.PA

France Health Care Nano Cap Report: 2023 Annual

Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 28 full-time employees. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.

Key Statistics of Acticor Biotech SA (ALACT.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.25€0.25

Today's Open

€0.25

Volume

13.80K

P/E Ratio (TTM)

52 Week Range

€0.25€0.25

Market Cap

3.94M

Avg. Volume

14.50K

Dividend Yield

Financial Metrics & Statements of Acticor Biotech SA (ALACT.PA)

FAQ's for Acticor Biotech SA (ALACT.PA)

According to Musaffa’s Shariah screening methodology, Acticor Biotech SA (ALACT.PA) is currently classified as NOT HALAL as of September 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.